Radioactive treatment of a murine melanoma using a (32)P-patch.
OBJECTIVE
To evaluate the therapeutic effects of a (32)P-patch in the treatment of a murine melanoma.


METHODS
Thirty male C57BL6 mice were divided into two groups: treated and control. Superficial tumors were induced in both groups by injecting B16F1 melanoma at about 10 cells/mouse subcutaneously. Tumors developed 10-15 days after transplantation and the (32)P-patch was applied on palpable tumors of the treated group. Tumor growth was followed up in both groups by measuring tumor size with a caliper. After the follow-up period, the animals were killed and tumor samples of the treated and control groups were collected for histological study by preparing paraffin sections stained with hematoxylin-eosin.


RESULTS
The (32)P-patch showed the absence of radioactivity leakage in vitro and the homogeneous distribution of the radionuclide. The skin surface at the application site of the (32)P-patch appeared hairless, and erythema developed, but reversed to normal after a few days in the treated group. Control of tumor growth was achieved in the treated group compared with the control group, although complete remission did not occur.


CONCLUSIONS
The (32)P-patch tested for the treatment of a murine melanoma model showed its efficacy, as tumor growth was retarded after application of the patch Nevertheless, adjustment of some therapeutic parameters and/or combining the patch with other treatment modalities may be necessary to achieve complete regression. The P-patch represents a powerful tool to individualize the treatment of melanoma.
Salgueiro
María Jimena
MJ
Radioisotope Laboratory, Physics Department, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina. jsalgueiro@ffyb.uba.ar
Collia
Nicolás
N
Barreiro
María L Arcos
ML
Medina
Vanina
V
Nicolini
Jorge
J
Cremaschi
Graciela
G
Zubillaga
Marcela
M
D000287:Administration, Topical; D000818:Animals; D001918:Brachytherapy; D045744:Cell Line, Tumor; D019583:Dose Fractionation, Radiation; D008297:Male; D008545:Melanoma / Q000473:pathology / Q000532:radiotherapy*; D051379:Mice; D010761:Phosphorus Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use*; D011849:Radioactive Tracers; D012878:Skin Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D047368:Tumor Burden
D010761:Phosphorus Radioisotopes; D011849:Radioactive Tracers